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Background: Recently, a growing number of novel genetic defects underlying primary
immunodeficiencies (PIDs) have been identified, increasing the number of PID up to
more than 250 well-defined forms. Next-generation sequencing (NGS) technologies and
proper filtering strategies greatly contributed to this rapid evolution, providing the possibility to rapidly and simultaneously analyze large numbers of genes or the whole exome.
Objective: To evaluate the role of targeted NGS and whole exome sequencing (WES)
in the diagnosis of a case series, characterized by complex or atypical clinical features
suggesting a PID, difficult to diagnose using the current diagnostic procedures.
Methods: We retrospectively analyzed genetic variants identified through targeted NGS
or WES in 45 patients with complex PID of unknown etiology.
results: Forty-seven variants were identified using targeted NGS, while 5 were identified using WES. Newly identified genetic variants were classified into four groups: (I)
variations associated with a well-defined PID, (II) variations associated with atypical
features of a well-defined PID, (III) functionally relevant variations potentially involved in
the immunological features, and (IV) non-diagnostic genotype, in whom the link with
phenotype is missing. We reached a conclusive genetic diagnosis in 7/45 patients
(~16%). Among them, four patients presented with a typical well-defined PID. In the
remaining three cases, mutations were associated with unexpected clinical features,
expanding the phenotypic spectrum of typical PIDs. In addition, we identified 31 variants
in 10 patients with complex phenotype, individually not causative per se of the disorder.
conclusion: NGS technologies represent a cost-effective and rapid first-line genetic
approach for the evaluation of complex PIDs. WES, despite a moderate higher cost
Abbreviations: ACMG, American College of Medical Genetics; ALPS, autoimmune lymphoproliferative syndrome; CMC,
chronic mucocutaneous candidiasis; MYD88, myeloid differentiation factor 88; NGS, next-generation sequencing; PIDs,
primary immunodeficiencies; SNVs, single nucleotide variants; TLR, toll-like receptor; T-NGS, targeted next-generation
sequencing; WES, whole exome sequencing; WGS, whole genome sequencing.
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compared to targeted, is emerging as a valuable tool to reach in a timely manner, a
PID diagnosis with a considerable potential to draw genotype–phenotype correlation.
Nevertheless, a large fraction of patients still remains without a conclusive diagnosis. In
these patients, the sum of non-diagnostic variants might be proven informative in future
studies with larger cohorts of patients.
Keywords: primary immunodeficiencies, genetic diagnosis, targeted next-generation sequencing, whole exome
sequencing, genotype–phenotype correlation

INTRODUCTION

Here, we report on a case series of 45 complex or atypical
clinical phenotypes that were suggestive of PID, but difficult
to diagnose in a timely manner using the current diagnostic
procedures. Our aim was to use current NGS technology to help
diagnose PID in this cohort of patients. We used T-NGS and WES
in 27 and 18 patients, respectively.

Primary immunodeficiencies (PIDs) represent a heterogeneous
group of monogenic disorders including more than 250 genetically defined diseases, mostly identified in recent years (1–3).
A significant contribution to this rapid evolution is due to the
integration of functional studies with the use of next-generation
sequencing (NGS) technologies. The specific objective of this
strategy is the identification of putative pathogenic alterations in
known or novel genes implicated in well-defined biological pathways (4–7). However, despite the breadth of current knowledge,
the diagnostic approach used for the identification of genetic
causes underlying PID appears inefficient and time-consuming
as the majority of PID cases remain without a diagnosis even
after extensive clinical and genetic investigations (8). Moreover,
even in a single PID gene mutation, a genotype–phenotype correlation is often missing, because various clinical phenotypes
may be related to the same genetic defect and vice versa (9, 10).
Nevertheless, early diagnosis in severe forms of PIDs is crucial to
establish a proper treatment and improve the overall outcome (11,
12). In the traditional approach to PIDs, the molecular diagnosis
has long been based on the sequencing of multiple genes by the
Sanger method, a time-consuming strategy, which often results in
delayed diagnosis (13).
Next-generation sequencing technology has become a valuable first-line diagnostic tool for the timely diagnosis of genetic
disorders, in particular for complex clinical presentation (14).
NGS allows rapid, cost-efficient, accurate, and high-throughput
sequencing of millions of DNA fragments in a reasonably short
time. Whole exome sequencing (WES) is limited to the coding regions and splice junctions of the genome, which despite
accounting for only ~2% of the genome, contain about 85% of
genetic alterations known as responsible for human diseases (15).
In PIDs, a targeted sequencing approach, restricted only to
specific genes or to specific regions of interest is a reasonable
possibility to identify putative pathogenic variants that explain
a specific disorder, their related altered biological pathway, and
the array of genes that are transcribed. This can be the first-line
alternative as it involves a smaller dataset than WES or whole
genome sequencing (WGS) and is easier for the management of
the datasets (16–18). However, as the spectrum of distinct clinical
entities and the presenting phenotypes are expanding because of
the discovery of novel genes and of the identification of wider
clinical phenotypes, the differential diagnosis and subsequent
diagnostic targets must improve in parallel. This perspective
makes the whole exome or genome sequencing strategy attractive
options for the diagnosis of patients with PID (19).
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MATERIALS AND METHODS
Patients

We have studied 45 patients with a clinical history highly
suggestive of a primary immunological defect, that were
heterogeneous for ethnic origin, age, and sex. The patients were
selected on the basis of clinical features and abnormal immune
parameters (20). The clinical criteria included one or more of
the following features: opportunistic infections, granuloma,
chronic mucocutaneous candidiasis (CMC), intractable diarrhea, bronchiectasis, and severe autoimmunity. These symptoms
were associated, in some patients, with non-immunological
features. In six patients, a positive family history for a similar
phenotype was observed. Clinical criteria were considered
if associated with one or more of the following quantitative
and/or qualitative immunological abnormalities: abnormal
lymphocyte subsets (absolute count <2 SD of normal values
according to ESID criteria); proliferative response to mitogens
<10% of the levels measured in the control subject; absent/poor
specific antibody response; hypogammaglobulinemia; elevated
IgE levels (>2000 kU/l); severe impairment of cytolytic activity; and alteration of class switch recombination (CSR) with or
without hyper-IgM. PID patients, selected on the basis of the
above specified criteria, were subsequently grouped on the basis
of NGS results, functional alterations, and consistency between
genotype, phenotype, and immune assays.
The study was approved by the Institutional Ethical
Committee “Carlo Romano” of Federico II University and by
Ethical Committee of Spedali civili (Brescia) and conducted after
informed consent was obtained.

DNA Extraction and Sequence Capture
Array Design

Genomic DNA was isolated from peripheral blood lymphocytes
with QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany).
Quantity and quality were determined through the Epoch
Microplate Spectrophotometer (BioTech Instruments, Winooski,
VT, USA). A panel of 571 genes, including 68 genes known or
predicted to be related to PIDs and/or immune regulation, was
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sequenced (Table S1 in Supplementary Material). Basically, broad
searches in literature, PubMed queries and expert suggestions
defined the gene panel. We used BioMart (Ontario Institute for
Cancer Research/European Bioinformatics Institute) to retrieve
the coordinates of all exons for the specified genes from Ensembl.
Coordinates were based on the current human reference genome
(hGRC37, hg19).

identification of genetic variants that were predicted to be damaging, along with consistent genotype–phenotype correlation,
mutations were validated by Sanger sequencing using standard
protocols. In 9 patients, we detected 11 variants that were confirmed by Sanger sequencing.

Next-Generation Sequencing and
Bioinformatics Analysis

In order to identify potential causal mutations, annotated variants were further prioritized based on the following criteria:

Additional Phenotype-Based Variant
Filtering Criteria

Samples were sequenced using either a targeted panel of 571
(TaGSCAN v2.0) or WES for enrichment. Briefly, TaGSCAN
samples were prepared for sequencing using Illumina’s TruSight
Inherited Disease panel according to manufacturer’s protocols
(Illumina, San Diego, CA, USA). Samples were sequenced to
at least 2.5 GB on an Illumina MiSeq with TruSeq MiSeq V3
reagents, yielding paired 250 nucleotide reads. Samples were
prepared for exome sequencing using the TruSeq HT library
preparation kit (Illumina; San Diego, CA, USA) followed by
exome enrichment using the xGen Exome Research Panel V1.0
(Integrated DNA Technologies; Coralville, IA, USA) according to
manufacturers’ protocols. Paired-end 2 bp × 125 bp sequencing
was completed on an Illumina HiSeq 2500 instrument in high
output mode using V4 Chemistry. Samples were sequenced to at
least 7 GB of data resulting in a minimum target coverage of 50×.
For all samples, sequence was assembled, aligned to reference
gene sequences based on human genome build GRCh37/UCSC
hg19, and analyzed using custom-developed software, RUNES
and VIKING (21).
Alignment, variant calling, and analysis were performed, as
described previously (21). In detail, variants were filtered by frequency and variant category (22). Variant analysis was confined
to coding and splice variants with a minor allele frequency (MAF)
of 1% or less in the CMH internal database, in the Exome Variant
Server (EVS)1 and Exome Aggregation Consortium (ExAC).2
Other tools used to restrict NGS analysis to a set of gene-associated regions relevant to clinical presentations, was symptomand sign-assisted genome analysis (SSAGA), which mapped the
clinical features in ill neonates and children to disease genes, and
Phenomizer databases (21, 23). Sorting Intolerant From Tolerant
(SIFT) and Polymorphism Phenotyping v2 (PolyPhen2) have
been used to provide information on the impact of the variants.

– homozygous or heterozygous variants already reported that
were related to any immunological clinical phenotype were
selected to be further investigated by functional studies and
validated by Sanger method;
– variants in genes implicated in a molecular pathway related to
the phenotype were considered if associated with any functional alteration, which was even partially consistent, with the
clinical phenotype;
– all the genetic variants of genes that were probably unrelated
to the molecular pathway suspected to be involved in the
pathogenesis of the disease were excluded from the functional
studies, but reported in an ad hoc repository.

RESULTS
NGS of 45 Patients

Genomic DNA from 27 patients was enriched for all exons from
571 genes, including genes involved in immunological pathways,
while DNA from 18 patients was enriched for all nucleotides of
the exome. DNA from six patients, analyzed with TaGSCAN, was
subsequently sequenced for the entire exome and the bioinformatic analysis of data results is currently ongoing. For TaGSCAN,
98.9% of base pairs targeted had at least 10× coverage. Mean depth
of coverage was 580×. WES covered 97.05% of exonic regions
at 10× or greater on average. The overall analytic sensitivity for
single nucleotide variants (SNVs) was 98.7%.
The results of NGS exon sequencing are shown in Tables 1–4.
After bioinformatics analysis and filtering, the potential causative
nucleotide changes needed to be further evaluated in each individual patient (Table 5). All of these variants were SNVs or small
indel variants, with no other alteration such as large deletions or
insertions identified.
A satisfying molecular diagnosis of PID was achieved in 7
of the 45 patients (16%), including 3 patients with an atypical
presentation. Three causative variations were identified through
T-NGS, while five through WES. On the basis of the genetic
findings and of the clinical phenotypes, patients were divided
in four groups. Group 1 included subjects with a diagnostic
genotype that was previously associated with an immunological and/or clinical phenotype already reported for that genetic
disease. Group 2 included subjects with a diagnostic genotype
associated with novel or atypical clinical features of a genetic
disease. In the group 3, NGS revealed multiple genetic variants
that were consistent only with some features of the clinical and
immunological phenotype. Group 4 included patients with a
complex unclassified disorder that was associated with multiple

Functional Assays and Sanger Validation

Functional assays were performed to prove the impact of variants identified by NGS. Functional studies included lymphocyte
proliferation assays performed through [3H]thymidine incorporation assay, natural killer cell-mediated lysis of target cells
and lymphocyte apoptosis induced by FAS death receptor crosslinking, evaluated through flow cytometry, cytokines production
after toll-like receptors (TLR) stimulation, evaluated through
real-time PCR. Furthermore, protein expression was evaluated
through western blot analysis and standard procedures. After
1
2

http://evs.gs.washington.edu/EVS.
http://exac.broadinstitute.org/.
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TABLE 1 | Genetic variants associated with typical PID.
Patient

NGS method

Gene

Mutation

Protein

Zygosity

Inheritance

Clinical and immunological phenotype

001

T-NGS

CD40LG

c.373C>T

p.His125Tyr

Hom

XL

Severe hypogammaglobulinemia with hyper-IgM, neutropenia,
P. jirovecii pneumonia, CMV infection, intractable diarrhea

002

WES

STAT1

c.847T>A

p.Leu283Met

Het

AD

Chronic mucocutaneous candidiasis, recurrent pneumonia,
hypothyroidism, lymphopenia, poor vaccine response

003

WES

BTK

c.1105C>T

p.Leu369Phe

Hom

XL

Agammaglobulinemia

004

T-NGS

JAK3

c.856C>T

p.Gln286Ter

Hom

AR

T−B+NK−SCID, chronic diarrhea, poor proliferative response to
mitogens, IgA deficiency

CD40LG and JAK3 variants were identified with T-NGS and STAT1 and BTK variants identified with WES. These variations were found in patients with clinical phenotype of classic
well-defined PIDs.

TABLE 2 | Genetic variants associated with novel features of PID.
Patient

NGS
method

Gene

Mutation

Protein

Prediction score

Zygosity

Inheritance

Clinical and immunological phenotype

005

T-NGS

MYD88

c.192_194del

p.Glu66del

–

–

Hom

AR

Chronic yersiniosis and terminal ileitis, recurrent
severe cutaneous granulomatous abscesses,
hyper IgE, hypereosinophilia, neutropenia

006

WES

PLDN

c.232C>T

p.Q78X

–

–

Hom

AR

Partial oculocutaneous albinism,
nystagmus, recurrent cutaneous infections,
thrombocytopenia, leukopenia, NK deficiency

007

WES

DOCK8/
CLEC7A

c.3193delA

p.Ser1065Ala

–

–

Hom/Hom

AR

Intractable diarrhea, eczema, malignancy, food
allergies, hyper IgE, lymphopenia

SIFT PolyPhen2

X17/p.Tyr238X

MYD88 variant was identified through T-NGS in a patient with atypical features of MyD88 deficiency, presenting with chronic yersiniosis. PLDN variant was identified through WES
in a patient with incomplete features of Hermansky–Pudlak type II syndrome and impairment of NK cytolytic activity. DOCK8/CLEC7A variants were identified for the first time in a
patient with intractable diarrhea, malignancy, and features of Hyper IgE syndrome.

TABLE 3 | Genetic variants potentially involved in the immunological features.
Patient

NGS
method

Gene

8

T-NGS

UNC13D
CASP10

c.335G>C
c.683C>T

p.Cys112Ser
p.Pro228Leu

9

T-NGS

CASP10

c.1202_1208del

p.Cys401LeufsTer15

10

T-NGS

DOCK8
TLR3

c.1907A>G
c.2672A>G

11

T-NGS

ADA
ERCC6

12

T-NGS

AP3B1
PRF1
ADAMTS13

Mutation

Protein

Prediction score

Zygosity

Major clinical features

SIFT

PolyPhen2

0.38
0.07

0.832
0.071

Het
Het

Acute lymphoblastic leukemia treated with
allogeneic HSCT, ethmoiditis, recurrent
lymphadenopathy, autoimmune cytopenia, arthritis,
hypogammaglobulinemia, hyper-IgM, IgA deficiency

–

–

Het

Alopecia universalis, hyperthyrotropinemia, type
I diabetes mellitus, dental enamel hypoplasia,
developmental delay, short stature, candidiasis,
hepatomegaly, multiple skeletal abnormalities,
myopia, dysmorphic features, microcephaly,
abnormal FAS-induced apoptosis. Hyper IgE

p.Lys636Arg
p.His891Arg

0.4
0.01

0.057
0.309

Het

Inflammatory bowel disease, short stature,
aspergillosis, EBV infection, low CD4+ lymphocyte
subset, increased CD4 CD8 double-negative T
cells, normal antibody response

c.377C>A
c.1047A>G
c.3262A>G
c.2697G>A

p.Pro126Gln
p.K349=
p.Ser1088Gly
p.T899=

0

0.999
–
0.001
–

Het

–
0.48
–

T−B+NK− SCID treated with bone marrow
transplantation, P. jirovecii pneumonia, recurrent
otitis, absent ossicular bone with hypoacusia of the
right ear, mild brain, and cerebellar atrophy, speech
delay, scoliosis

c.787G>T
c.695G>A
c.272C>T
c.2701G>T

p.Gly263Cys
p.Arg232His
p.Ala91Val
p.Ala901Ser

0.05
0.02
0.01
0.61

0.932
0.991
0.808
0.049

Het

Interstitial lung disease CMV infection, esophageal
candidiasis, strabismus, abnormal expression of
perforin in NK cells, reduction of CD4+ cells with
increase of CD19+, normal proliferative response to
mitogens, normal antibody response

In this group of patients, T-NGS allowed to identify multiple variants not causative of a specific PID, but with a possible impact on the disease.
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TABLE 4 | Genetic variants not causative of PID with undetermined impact on the disease.
Patient

NGS
method

Gene

Mutation

13

T-NGS

CFTR

c.2991G>C

14

T-NGS

SYCE2
LYST

15

T-NGS

16

T-NGS

Protein

Prediction score

Zygosity

Major clinical features

SIFT

PolyPhen2

p.Leu997Phe

0.08

0.18

Het

Late onset hypogammaglobulinemia, recurrent
pneumonia, bronchiectasis, chronic sinusitis, cervical
and mediastinal lymphadenopathy, recurrent abdominal
pain, hepatomegaly with low grade steatosis,
splenomegaly

c.577G>A
c.10235G>A

p.Val193Met
p.Arg3412His

0.28
0.02

0
0.997

Het

t(11;18)MLT1-AP12 gastric maltoma HP+, persistent
oral candidiasis, sinusitis; lung cystis, chronic cough,
recurrent fever, hypereosinophilia, recurrent itch,
recurrent myofasciitis, hyper-IgM, altered somatic
hypermutation, absent CD19+CD20− IgG+ (mature), low
CD19+CD27+IgM+ (memory), absent CD19+CD27+IgM−
(switched memory)

ATR
ARSA
CASP10
IKBIKG
MEFV
SP110
UNC13D

c.5257A>G
c.869G>A
c.683C>T
c.1165C>T
c.460T>C
c.1114C>T
c.335G>C

p.Ile1753Val
p.Arg290His
p.Pro228Leu
p.Pro389Ser
p.Ser154Pro
p.Arg372Ter
p.Cys112Ser

0.16
0.55
0.07
0.29
0.04
–
0.38

0.403
0.959
0.071
0.041
0.001
–
0.852

Het
Het
Het
Het
Het
Het
Het

Severe aplastic anemia, hepatomegaly, Legionella
sp. and Aspergillus recurrent pneumonia, metacarpal
deforming alterations with bone demineralization,
abnormal lymphocyte proliferation, dilated
cardiomyopathy, early retinopathy

ATRX
MYD88
DOCK8

c.2247_2249del
c.2133_2135del
c.10_28del
c.2920C>A
c.3016C>A
c.3220C>A

p.Ser750del
p.Ser712del
p.Ala6ProfsTer39
p.His974Asn
p.His1006Asn
p.His1074Asn

–
–
–
0.34
0.33
0.33

–
–
–
0.001
0.003
0.003

Het
Hom
Het
Het
Het
Het

Autoimmune adrenal insufficiency, autoimmune
thyroiditis, lymphadenopathy, autoimmune
thrombocytopenia, and neutropenia

0.27

0.006

Het

Hypogammaglobulinemia, familial IgA deficiency, hyper
IgE, multiple bronchiectasis, candidiasis
Familial IgA deficiency, multiple bronchiectasis,
recurrent respiratory infections, low IgM levels

17

T-NGS

TYK2

c.3488A>G

p.Glu1163Gly

18

T-NGS

TLR3

c.634-10C>A
Intron

–

19

T-NGS

CASP10
ERCC5
GJC2
PEX26
RAB23
UBR1

c.1094A>C
c.2375C>T
c.256G>A
c.728C>T
c.536A>C
c.3290C>T

p.Tyr365Ser
p.Ala792Val
p.Val86Ile
p.Ala243Val
p.Glu 179Ala
p.Thr1097Met

0
0
0.13
–
–
–

0.982
1
0.825
–
–
–

Het
Het
Het
Het
Het
Het

Mild hypogammaglobulinemia, undetectable CD16+
lymphocyte levels, pervasive developmental disorder

20

T-NGS

CD3-ZETA c.301C>T
OCRL
c.2032A>G

p.Gln101Ter
p.Ser678Gly

–
0

–
0.986

Het
Hem

Hypogammaglobulinemia, recurrent pneumonia,
transient alopecia, behavioral disorders, oropharyngeal
candidiasis

21

22

T-NGS

T-NGS

–

–

Het

PKHD
NPHP3
G6PC

c.5125C>T
c.2864del
c.634A>G

p.Leu1709Phe
p.Asp955ValfsTer2
p.Ile212Val

0.15
–
0.88

1
–
0.01

Het
Het
Het

Multi-organ failure and hypocalcemia during EBV
infection, persistent EBV infection, kidney single cystic
formation, hyper IgE, normal antibody response and
proliferative response to mitogens, normal perforin
intracytoplasmic expression, normal degranulation
assay, reduced production of IFNγ

RAB27
LYST

c.418C>G
c.6482A>C

p.Gln140Glu
p.Glu2161Ala

1
0.03

0.24
0.002

Het
Het

Recurrent fever, oral aphthous, diarrhea, laterocervical
lymphadenopathy, hepatomegaly, increased level
of amyloid protein, recurrent pneumonia, increased
level of IgA, hyper IgE increased double-negative
lymphocytes, normal functional Fas assay

In this fourth group, T-NGS led to identify multiple genotypic alterations in patients showing complex phenotypes, which could not fit into defined clinical syndromes. In this group, no
genotype–phenotype relationship was possible. However, since these cases are extremely rare, these data should likewise be collected in a database for future studies pointing to
the sum of alterations on the whole.

genetic variants, each of them, individually, was not per se
causative of the disorder. However, regarding the variants of
groups 3 and 4, it should be pointed out that, since parental
cosegregation studies were not performed, the variants may

Frontiers in Immunology | www.frontiersin.org

not be truly disease-causing or disease-modifying alterations,
especially if inherited together from an unaffected parent.
The first group included four subjects who have been identified for a genetic defect associated with a known well-established
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TABLE 5 | Gene variants confirmed by Sanger sequencing, functional assays and/or previous report.
Gene

Mutation

Sanger confirmation

Functional assays

Reference

CD40LG
BTK
STAT1
JAK3
MYD88

c.373C>T
c.847T>A
c.1105C>T
c.856C>T
c.192_194del

Yes
Yes
Yes
Yes
Yes

PLDN
DOCK8/CLEC7A
UNC13D
CASP10
CASP10
DOCK8
TLR3
ADA
ERCC6
AP3B1
PRF1
ADAMTS13

c.232C>T
c.3193delA
c.335G>C
c.683C>T
c.1202_1208del
c.1907A>G
c.2672A>G
c.377C>A
c.3262A>G
c.787G>T
c.695G>A
c.2701G>T

Yes
Yes
NA
NA
Yes
NA
NA
NA
NA
NA
Yes
NA

Absent expression of CD40L after stimulation
NA
IFNα- and IFNγ-induced increased level of pSTAT1
Abnormal proliferative response to mitogens
Reduced levels of IL-6, IL-1, CCL2, and CCL3 after TLR
stimulation with LPS, IL-1, TNFα; rescue of IL-1β and LPS
responsiveness after WT MYD88 gene transfection
Absent PLDN protein expression
Low level of DOCK8 protein expression
NA
NA
Abnormal Fas-induced apoptosis in PHA-activated T cells
–
Normal INFγ production after TLR3 stimulation
Abnormal proliferative response to mitogens
NA
NA
Reduced expression of perforin in NK cells
NA

(24)
(25)
(26)
–
(27, 28)

(29, 30)
(31)
(32)
–
–
–
–
(33, 34)
–
–
(35)
–

For each variant, the Sanger confirmation, the functional assays, and references for variants already published were reported.
NA, not applied.

immunological and/or clinical phenotype of PID (Table 1). In
detail, variants in CD40LG, BTK, STAT1 genes were already
reported in literature as pathogenic (24–26). The JAK3 nonsense
variant was predicted to result in nonsense-mediated decay
resulting in no protein expression. This mutation, though not
previously reported, was fully congruent with the classic JAK3–
SCID phenotype observed in multiple affected family members
who shared the same genotype (proband and two siblings).
The second group included other three subjects in whom
genetic variants were found as associated with novel phenotypic
features, in previously characterized phenotypes (Table 2).
Specifically in this group, patient 005 was found to carry a homozygous mutation in MYD88 (c.192_194del; p.Glu66del), previously
reported in several MYD88 deficiency affected families (27, 28).
This patient was of a Rom ethnicity and had inherited the deletion
from his unaffected consanguineous parents. But, early infant
deaths due to severe infections were observed in the same family
pedigree. Functionally, known mutations result in impairment of
cytokine production after TLR stimulation (36, 37). Patients 006
and 007 were found to carry homozygous deleterious mutations
in PLDN and DOCK8/CLEC7A gene, respectively, whose phenotypic peculiarity has been described in detail (29, 31).
The third group of subjects included five patients who carried multiple heterozygous variants affecting genes expressed
in the hematopoietic system that were not consistent with a
specific PID (Table 3). However, some of these patients might
harbor a second mutation that was not identified by NGS or
Sanger sequencing. In patient 008, we observed a heterozygous, probably, pathogenic variant in UNC13D (c.335G>C
p.Cys112Ser), and a heterozygous, most likely benign variant
in CASP10 gene (c.683C>T p.Pro228Leu; exon 10 not covered). This patient had a clinical phenotype consistent with an
autosomal dominant type II ALPS (ALPS-II), associated with
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hypogammaglobulinemia and acute lymphoblastic leukemia.
Even though the CASP10 variant alone in the in silico prediction
programs, PolyPhen2 and SIFT, was predicted to be tolerated and
was observed in 35 healthy individuals (ExAC), its significance
in association with the second deleterious variant in UNC13D
has never been described and could be potentially relevant.
In fact, this UNC13D variant has been previously reported in
association with heterozygous mutation of FAS and is considered
a disease modifier for ALPS (32). In patient 009, we found by
T-NGS a heterozygous frameshift variant in CASP10 causative
of ALPS-II and categorized as likely pathogenic according to
American College of Medical Genetics (ACMG) criteria (22).
His immunological phenotype was characterized by very high
IgE levels (>2000 IU). The functional analysis of Fas-induced
apoptosis in PHA-activated T cells from the patient confirmed
that the apoptotic pathway was impaired, since cell apoptosis
upon triggering of Fas was impaired (92% survival; normal
values: median 60%, 95th percentile 82%). His brother, who
presented with similar manifestations, died early in life because
of hemophagocytic lymphohistiocytosis. In addition, the patient
009 also had additional clinical features, such as developmental
delay, microcephaly, peculiar facial dysmorphism, and skeletal
abnormalities, which could not be at moment demonstrated or
excluded to be directly explained by the variant. In patient 010,
we found two heterozygous variants of unknown significance
in DOCK8 and TLR3 with good coverage of each gene and
no second variant. The TLR3 variant had multiple lines of
computational evidence supporting a deleterious effect on gene/
protein. Further studies are ongoing to find a possible correlation
between the association of the two variants with the clinical phenotype, which was characterized by inflammatory bowel disease,
susceptibility to viral infections, aspergillosis, T-cell lymphopenia, and increased CD4 and CD8 double-negative T cells.
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Alternatively, a second unidentified mutation of DOCK8 might
account for the clinical manifestations of the patient. In patient
011 with a T−B+NK− SCID phenotype associated with deafness,
microcephaly, brain and cerebellar atrophy, developmental delay,
NGS revealed 2 heterozygous mutations of ADA gene, located
in the same allele, the first one being likely pathogenic, and a
further heterozygous variant of unknown significance of ERCC6
gene. The latter gene, which encodes for Cockayne syndrome B
protein, has been recently described as essential for postnatal
neuronal differentiation and neuritogenesis (38). Intriguingly,
the patient showed also some neurological manifestations,
such as macrocephaly and moderate grade cerebral atrophy. In
patient 012 affected with hemophagocytic lymphohistiocytosis
and marked reduction of perforin expression in NK cells, we
identified two heterozygous mutations in PRF1 that were located
in the same allele as shown by Sanger sequencing. In the same
patient, we have also detected heterozygous variants in AP3B1
and ADAMTS13 genes that have been implicated in NK activity
as well.
The last group of patients included 10 patients with a complex
disorder that was not typical of any known syndrome and was
associated with multiple genetic variants, each of them was not
per se causative individually of that disorder (Table 4). In this
group, it was not possible to draw any correlation between the
genetic variations that were detected and the pathogenesis of
the disorders. However, these alterations of unknown biologic
significance were found in several genes implicated in immunological functions at different extent.
In the remaining 23 patients who were analyzed by NGS,
including 9 studied by T-NGS and 15 by WES, we could not
identify any candidate variants. These unsolved datasets will be
re-analyzed when new bioinformatics tools become available and
as new disease genes are described.

We have divided NGS results into four categories: (I) genetic
alterations associated with a canonical PID phenotype,
(II) diagnostic genotype in atypical presentation, (III) genetic
variants potentially involved in the immunological features,
and (IV) multiple genetic variants, each of them was not per se
causative individually of the disorder, even though the sum of
variations of the different genes could be proven in the future
of some pathogenic significance, as either causative or modifier
factor.
The first and second groups included patients whose candidate
genotypes were congruent with the immunologic features suggesting a causal relationship. Of note, exome sequencing allowed
the identification of PLDN variants associated with a novel
genetic cause of partial albinism and with PID (29). This study
reported six patients who had undergone a diagnostic odyssey
of 10–21 months driven by worldwide accepted protocols (40).
Unfortunately, this candidate gene approach, although functionally driven, failed to yield a diagnosis. The diagnosis was finally
made possible with NGS technology in a much more timely
manner (2 months).
In the second category of patients, which included patients
carrying genetic variants previously reported, but associated
with novel features of previously established phenotypes, the
molecular definition of the diagnosis contributed to expanding
the overall knowledge of pathogenetic mechanisms underlying
that specific disorder. In the patient with MYD88 deficiency, the
atypical presentation was characterized by chronic yersiniosis
resulting in terminal ileitis and recurrent neutropenia, in the
absence of invasive pneumococcal disease, as is expected in
this rare immunodeficiency. The atypical clinical presentation
was responsible for the diagnostic delay. Moreover, Sanger
sequencing of four candidate genes (STAT3, ELANE, RAG1, and
RAG2) had given negative results (27). Homozygous mutations
of DOCK8 and CLEC7A were already reported as genetic cause
of two distinct PIDs, such as autosomal recessive Hyper IgE
syndrome and of CMC, respectively, but never observed in a
single patient. It is likely that these genetic variants affecting two
distinct loci, and probably concurring to the clinical manifestations of the patient, could not be identified without the availability of NGS (31).
The cases highlighted herein contribute to the explanation of
several phenotypes for very rare disorders. Such broadening of
the phenotypic spectrum is a phenomenon shared with many
other rare disorders, as atypical patients are identified through
NGS. In the case of congenital immune disorders, at the beginning only the most severe forms are described (41). Only after
years from the initial description of the syndrome milder features
of the disease are recognized or extra-immunological clinical
signs identified.
In the third group, NGS sequencing revealed multiple heterozygous genetic variants in each subject, some of them potentially involved in the immunological features. All the variants of
this group are either single heterozygous or in cis, thus further
studied are needed, including WES or microarray testing to try
to find the second mutation or uncover mutation(s) in a separate
gene that fully explain(s) the phenotype. In the patient 012, the
PRF1 gene alteration was proven to have functional relevance,

DISCUSSION
The advent of NGS technologies has given the possibility to
physicians to investigate multiple genes assay, to provide great
opportunities for diagnosing patients affected with complex
disorders of the immune system, and to increase our knowledge
on the pathogenesis of these genetic disorders (39).
In this study, we used NGS technologies to identify potential
disease-causing mutations in patients affected with clinical
phenotypes highly suggestive of a PID, which were still not
diagnosed after using traditional sequential Sanger sequencing
procedures. Thanks to this novel diagnostic approach, we report
that a definitive diagnosis of PID was achieved in a timely manner in 7 out of the 45 subjects. In three patients, the diagnosis
was achieved through T-NGS, while, in the other four patients,
the diagnosis was reached by WES. In all these subjects, the
application of a clear-cut filtering strategy, consisting of targeted
sequencing, bioinformatics analysis, phenotype-based filtering criteria, and confirmartory functional assays and Sanger
sequencing, led to the identification of the underlying immune
disorder (Figure 1). With this approach, eight of the overall
group of variants resulted in potentially disease-causing mutations, distributed over seven patients.
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FIGURE 1 | Flowchart of the filtering strategy. A schematic overview of the approach/clear-cut strategy used to filter variants identified through T-NGS or WES
in order to identify potentially causative mutations.

since perforin expression in NK cells was reduced. However, the
patient was not placed in the group 1 since the two heterozygous
PRF1 variations were in cis at the Sanger sequencing. Previously,
our group has documented that this heterozygous variation may
act as a susceptibility cofactor, which under certain circumstances
may be associated with a functional alteration (42).
Finally, the fourth group included patients showing multiple
genotypic alterations associated with complex phenotypes that
could not fit into defined clinical phenotypes. In this group, no
genotype–phenotype relationship was possible. However, since
these cases are extremely rare, these data should likewise be
collected in a database. The creation of such a database might
improve the interpretation of NGS results in those cases currently
interpreted as no causative of the disorder. The identification of
different individuals with the same phenotype and mutations in
the same array of genes would suggest that the sum of variations
in different genes exerts a pathogenic role, either as causative or
as modifier factor.
However, even though in our study in 7 out of the 45 patients,
a diagnosis was achieved, it should be considered that in the
majority of the patients, target NGS approach did not allow to

Frontiers in Immunology | www.frontiersin.org

identify the genetic basis of the disease. Several aspects should
be considered to interpret this observation. The first limitation
is the limited number of the genes included on our targeted
NGS panel. Moreover, the sequencing techniques do not provide
enough coverage for intronic, promoter, or regulator regions. To
overcome these technical limitations, whole exome or genome
sequencing might be better strategies to deeply investigate these
cases as the second-line diagnostic tool (14). Moreover, all NGS
techniques, due to the generation of short reads, show a low
sensitivity to detect complex structural variations (deletions,
insertions, and inversions), repeat sequences, or complex rearrangement (43).
Based on these considerations, the identification of genetic
defects in patients with PIDs is still a major challenge, and the
functional implication of the variation must be considered mandatory to definitely prove the relationship between the genetic
alteration and the related phenotype.
Despite the above mentioned limitations, NGS technology
represents a cost-effective and rapid first-line genetic approach
for the evaluation of complex cases of PIDs. The advantage of
this technique is the simultaneous sequencing of a panel of genes,

8

November 2016 | Volume 7 | Article 466

Gallo et al.

Next-Generation Sequencing in Primary Immunodeficiencies

perhaps leading to the rapid identification of a diagnosis that may
not have been otherwise considered using the traditional phenotype-driven approach. Overall, in spite of a moderately higher
cost, at moment WES could represent the first-line approach
to initial PID management. The sequential investigation of
several candidate genes is, by comparison, a very time- and costconsuming process. Prompt diagnosis shows an unquestioned
clinical advantage, allowing initiation of appropriate and often
life-saving treatment.
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